WOCKPHARMA Wockhardt Ltd Earnings Reports Announcement 2024 - Financial Results Q2 Wockhardt Limited announces its unaudited financial results for Q2 FY25, showing a 7% revenue growth to INR 818 Cr and a 71% EBITDA growth to INR 139 Cr from the previous year, with a successful clinical trial almost complete for its novel antibiotic, ZAYNICH..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Wockhardt Ltd